Base de dados : MEDLINE
Pesquisa : C04.557.450.565.575.650.800 [Categoria DeCS]
Referências encontradas : 6155 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 616 ir para página                         

  1 / 6155 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29385199
[Au] Autor:Schaefer C; Mallela N; Seggewiß J; Lechtape B; Omran H; Dirksen U; Korsching E; Potratz J
[Ad] Endereço:Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany.
[Ti] Título:Target discovery screens using pooled shRNA libraries and next-generation sequencing: A model workflow and analytical algorithm.
[So] Source:PLoS One;13(1):e0191570, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In the search for novel therapeutic targets, RNA interference screening has become a valuable tool. High-throughput technologies are now broadly accessible but their assay development from baseline remains resource-intensive and challenging. Focusing on this assay development process, we here describe a target discovery screen using pooled shRNA libraries and next-generation sequencing (NGS) deconvolution in a cell line model of Ewing sarcoma. In a strategy designed for comparative and synthetic lethal studies, we screened for targets specific to the A673 Ewing sarcoma cell line. Methods, results and pitfalls are described for the entire multi-step screening procedure, from lentiviral shRNA delivery to bioinformatics analysis, illustrating a complete model workflow. We demonstrate that successful studies are feasible from the first assay performance and independent of specialized screening units. Furthermore, we show that a resource-saving screen depth of 100-fold average shRNA representation can suffice to generate reproducible target hits despite heterogeneity in the derived datasets. Because statistical analysis methods are debatable for such datasets, we created ProFED, an analysis package designed to facilitate descriptive data analysis and hit calling using an aim-oriented profile filtering approach. In its versatile design, this open-source online tool provides fast and easy analysis of shRNA and other count-based datasets to complement other analytical algorithms.
[Mh] Termos MeSH primário: Descoberta de Drogas/métodos
Avaliação Pré-Clínica de Medicamentos/métodos
Biblioteca Gênica
RNA Interferente Pequeno/genética
[Mh] Termos MeSH secundário: Algoritmos
Linhagem Celular Tumoral
Biologia Computacional
Células HEK293
Sequenciamento de Nucleotídeos em Larga Escala
Seres Humanos
Lentivirus/genética
Interferência de RNA
Sarcoma de Ewing/tratamento farmacológico
Sarcoma de Ewing/genética
Análise de Sequência de RNA
Fluxo de Trabalho
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (RNA, Small Interfering)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191570


  2 / 6155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29178401
[Au] Autor:Nakata K; Ito Y; Magadi W; Bonaventure A; Stiller CA; Katanoda K; Matsuda T; Miyashiro I; Pritchard-Jones K; Rachet B
[Ad] Endereço:Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
[Ti] Título:Childhood cancer incidence and survival in Japan and England: A population-based study (1993-2010).
[So] Source:Cancer Sci;109(2):422-434, 2018 Feb.
[Is] ISSN:1349-7006
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The present study aimed to compare cancer incidence and trends in survival for children diagnosed in Japan and England, using population-based cancer registry data. The analysis was based on 5192 children with cancer (age 0-14 years) from 6 prefectural cancer registries in Japan and 21 295 children diagnosed in England during 1993-2010. Differences in incidence rates between the 2 countries were measured with Poisson regression models. Overall survival was estimated using the Kaplan-Meier method. Incidence rates for Hodgkin lymphoma, renal tumors and Ewing sarcomas in England were more than twice as high as those in Japan. Incidence of germ cell tumors, hepatic tumors, neuroblastoma and acute myeloid leukemia (AML) was higher in Japan than in England. Incidence of all cancers combined decreased in Japan throughout the period 1993 to 2010, which was mainly explained by a decrease in registration of neuroblastoma in infants. For many cancers, 5-year survival improved in both countries. The improvement in survival in chronic myeloid leukemia (CML) was particularly dramatic in both countries. However, 5-year survival remained less than 80% in 2005-2008 in both countries for AML, brain tumors, soft tissue sarcomas, malignant bone tumors and neuroblastoma (age 1-14 years). There were significant differences in incidence of several cancers between countries, suggesting variation in genetic susceptibility and possibly environmental factors. The decrease in incidence for all cancers combined in Japan was related to the cessation of the national screening program for neuroblastoma. The large improvement in survival in CML coincided with the introduction of effective therapy (imatinib).
[Mh] Termos MeSH primário: Neoplasias/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Neoplasias Ósseas/epidemiologia
Criança
Pré-Escolar
Inglaterra/epidemiologia
Doença de Hodgkin/epidemiologia
Seres Humanos
Incidência
Lactente
Recém-Nascido
Japão/epidemiologia
Neoplasias Renais/epidemiologia
Sarcoma de Ewing/epidemiologia
Análise de Sobrevida
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1111/cas.13457


  3 / 6155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29437069
[Au] Autor:Albergo JI; Gaston CLL; Parry MC; Laitinen MK; Jeys LM; Tillman RM; Abudu AT; Grimer RJ
[Ad] Endereço:Hospital Italiano de Buenos Aires, Peron 1190 (c1199abd), Buenos Aires, Argentina and Royal Orthopaedic Hospital, Bristol Road South, Birmingham B31 2AP, UK.
[Ti] Título:Risk analysis factors for local recurrence in Ewing's sarcoma: when should adjuvant radiotherapy be administered?
[So] Source:Bone Joint J;100-B(2):247-255, 2018 Feb.
[Is] ISSN:2049-4408
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: The aim of this study was to analyse a group of patients with non-metastatic Ewing's sarcoma at presentation and identify prognostic factors affecting the development of local recurrence, in order to assess the role of radiotherapy. PATIENTS AND METHODS: A retrospective review of all patients with a Ewing's sarcoma treated between 1980 and 2012 was carried out. Only those treated with chemotherapy followed by surgery and/or radiotherapy were included. Patients were grouped according to site (central or limb) for further analysis of the prognostic factors. RESULTS: A total of 388 patients were included in the study. Of these, 60 (15%) developed local recurrence at a mean median of 27 months (sd 24, range 7 to 150) and the five-year local recurrence-free survival (5yrLRFS) was 83%. For central tumours, the size of the tumour and histological response to chemotherapy were found to be significant factors for local recurrence. For limb tumours, local recurrence was affected by intralesional and marginal resections, but not by the histological response to chemotherapy. Radiotherapy in those with a marginal resection reduced the risk of local recurrence (5yrLRFS: 96% 81%, p = 0.044). CONCLUSION: Local recurrence significantly affects the overall survival in patients with a Ewing's sarcoma. For those with a tumour in a limb, radiotherapy reduced the risk of local recurrence, especially in those with a marginal margin of excision, but the effect in central tumours was less clear. Radiotherapy for those who have had a wide margin of resection does not reduce the risk of local recurrence, regardless of the histological response to chemotherapy. Cite this article: 2018;100-B: 247-55.
[Mh] Termos MeSH primário: Neoplasias Ósseas/radioterapia
Recidiva Local de Neoplasia/patologia
Radioterapia Adjuvante
Sarcoma de Ewing/radioterapia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Neoplasias Ósseas/tratamento farmacológico
Neoplasias Ósseas/cirurgia
Criança
Pré-Escolar
Feminino
Seres Humanos
Lactente
Masculino
Meia-Idade
Prognóstico
Estudos Retrospectivos
Fatores de Risco
Sarcoma de Ewing/tratamento farmacológico
Sarcoma de Ewing/cirurgia
Taxa de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180214
[St] Status:MEDLINE
[do] DOI:10.1302/0301-620X.100B2.BJJ-2017-0222.R1


  4 / 6155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29252749
[Au] Autor:Mahan MC; Frisch N; Durrant B; Parsons T; Woods T; Mott M
[Ad] Endereço:Department of Orthopaedic Surgery, Henry Ford Health System, Detroit, Michigan.
[Ti] Título:Ewing Sarcoma in the Fifth Metacarpal of an Adult Woman: A Case Report.
[So] Source:JBJS Case Connect;6(4):e95, 2016 Oct-Dec.
[Is] ISSN:2160-3251
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CASE: Atypical presentations of Ewing sarcoma (ES) can lead to misdiagnosis and delays in treatment. We present a rare case of ES in the hand of an adult woman who underwent multiple interventions prior to referral to our institution. At 22 months after definitive treatment, the patient remained pleased with the result and had no evidence of recurrence. CONCLUSION: To our knowledge, ES of the hand in an adult woman has not yet been reported in the literature, and a lack of recognition of this condition might be secondary to the absence of features traditionally associated with malignant bone neoplasms. A broader differential diagnosis after intervention failures offers the opportunity for diagnosis and appropriate treatment.
[Mh] Termos MeSH primário: Neoplasias Ósseas/terapia
Ossos Metacarpais/cirurgia
Sarcoma de Ewing/terapia
[Mh] Termos MeSH secundário: Neoplasias Ósseas/diagnóstico por imagem
Neoplasias Ósseas/patologia
Feminino
Seres Humanos
Ossos Metacarpais/diagnóstico por imagem
Ossos Metacarpais/patologia
Meia-Idade
Sarcoma de Ewing/diagnóstico por imagem
Sarcoma de Ewing/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.2106/JBJS.CC.16.00051


  5 / 6155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29252743
[Au] Autor:Riff AJ; Gross CE; Foucher KC; Kuo KN; Gitelis S
[Ad] Endereço:Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois.
[Ti] Título:Acetabular Osteoarticular Allograft After Ewing Sarcoma Resection: A 15-Year Follow-up: A Case Report.
[So] Source:JBJS Case Connect;6(4):e89, 2016 Oct-Dec.
[Is] ISSN:2160-3251
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CASE: A 4-year-old girl with Ewing sarcoma of the periacetabular region had been treated with neoadjuvant chemotherapy followed by resection and osteoarticular allograft reconstruction with an adult hemipelvis. At 15 years postoperatively, she remained disease-free with remarkable functionality. She had minimal groin pain and could walk an unlimited distance. Radiographs demonstrated union at the anastomotic junctions. The allograft, which had been considerably oversized 15 years ago, was now identical in size to the contralateral ilium. CONCLUSION: Osteoarticular allograft remains one of the best reconstructive options following hemipelvectomy in the pediatric population because of its potential durability and its capacity to restore pelvic stability and preserve functionality.
[Mh] Termos MeSH primário: Acetábulo/transplante
Neoplasias Ósseas/cirurgia
Sarcoma de Ewing/cirurgia
[Mh] Termos MeSH secundário: Aloenxertos
Cartilagem Articular/cirurgia
Desenvolvimento Infantil
Pré-Escolar
Seres Humanos
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.2106/JBJS.CC.16.00071


  6 / 6155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29328615
[Au] Autor:Radunovic A; Kosutic M; Vulovic M; Milev B; Janjusevic N; Ivosevic A; Krulj V
[Ti] Título:Ilizarov method as limb salvage in treatment of massive femoral defect after unsuccessful tumor arthroplasty.
[So] Source:Vojnosanit Pregl;73(8):779-82, 2016 Aug.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction: Surgical management of massive bone defects is very challenging in terms of estimating possibilities of saving the extremity and adequate method that can make it possible. Selection of methods is additionally limited in the presence of infection at site of defect. Case report: The female patient, diagnosed with Ewing sarcoma was treated by segmental bone resection and implantation of Kotz modular tumor endoprosthesis. After 5 years the signs of infection occured and persisted with low grade intensity. After falling, 12 years following implantation, the patient acquired periprosthetic fracture. Then endoprosthesis was removed, all along with surgical debridement of wound and application of the Ilizarov apparatus. The apparatus was applied, osteotomy of callus and the tibia performed with transport of bone segments, untill reconstruction of defect and arthrodesis of the knee was achieved. Conclusion: The Ilizarov apparatus offered us huge possibilities for management of massive bone defects with natural bone which has superior biomechanical characteristics comparing to the implant. The most frequent complication of this method is a prolonged treatment period that demands good patient selection and preparation and wide surgical experience.
[Mh] Termos MeSH primário: Neoplasias Femorais/cirurgia
Fêmur/cirurgia
Técnica de Ilizarov
Salvamento de Membro
Sarcoma de Ewing/cirurgia
[Mh] Termos MeSH secundário: Adolescente
Feminino
Fraturas do Fêmur/diagnóstico
Seres Humanos
Fraturas Periprotéticas/diagnóstico
Implante de Prótese
Infecções Relacionadas à Prótese/diagnóstico
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150419039R


  7 / 6155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28873262
[Au] Autor:Choo S; Wang P; Newbury R; Roberts W; Yang J
[Ad] Endereço:Division of Hematology/Oncology, Department of Pediatrics, University of California, San Diego, California.
[Ti] Título:Reactivation of TWIST1 contributes to Ewing sarcoma metastasis.
[So] Source:Pediatr Blood Cancer;65(1), 2018 Jan.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Ewing sarcoma is a cancer of bone and soft tissue. Despite aggressive treatment, survival remains poor, particularly in patients with metastatic disease. Failure to treat Ewing sarcoma is due to the lack of understanding of the molecular pathways that regulate metastasis. In addition, no molecular prognostic markers have been identified for Ewing sarcoma to risk stratify patients. PROCEDURE: Ewing sarcoma patients were divided into high or low Twist1 gene expression and survival curves were generated using the R2 microarray-based Genomic Analysis platform (http://r2.amc.nl). Tumors from Ewing sarcoma patients were also evaluated for TWIST1 expression by immunohistochemistry. Ewing sarcoma xenografts were established to evaluate the role of TWIST1 in metastasis. The effects of Twist1 on migration and invasion were evaluated using migration and invasion assays in A673 and RDES cells. RESULTS: Twist1 expression was a negative prognostic marker for overall survival in a public Ewing sarcoma patient data set based on Twist1 mRNA levels and in patient tumor samples based on Twist1 immunohistochemistry. TWIST1 is detected in significantly higher percentage of patients with metastatic diseases than localized disease. Using Ewing sarcoma tumor xenografts in mice, we found that suppressing TWIST1 levels suppressed metastasis without affecting primary tumor development. Knockdown of Twist1 inhibited the migration and invasion capability, while overexpression of Twist1 promoted migration and invasion in Ewing sarcoma cells. CONCLUSION: These results suggest that TWIST1 promotes metastasis in Ewing sarcoma and could be used as a prognostic marker for treatment stratification; however, further validation is required in a larger cohort of patients.
[Mh] Termos MeSH primário: Neoplasias Ósseas/metabolismo
Movimento Celular
Regulação Neoplásica da Expressão Gênica
Proteínas de Neoplasias/biossíntese
Proteínas Nucleares/biossíntese
Sarcoma de Ewing/metabolismo
Proteína 1 Relacionada a Twist/biossíntese
[Mh] Termos MeSH secundário: Animais
Neoplasias Ósseas/patologia
Linhagem Celular Tumoral
Feminino
Xenoenxertos
Seres Humanos
Masculino
Camundongos
Invasividade Neoplásica
Metástase Neoplásica
Transplante de Neoplasias
Sarcoma de Ewing/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neoplasm Proteins); 0 (Nuclear Proteins); 0 (TWIST1 protein, human); 0 (Twist-Related Protein 1)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180110
[Lr] Data última revisão:
180110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26721


  8 / 6155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28868758
[Au] Autor:Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
[Ad] Endereço:Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
[Ti] Título:Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
[So] Source:Pediatr Blood Cancer;65(1), 2018 Jan.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Programmed cell death 1 (PD-1) receptor engagement on T cells by its ligand programmed cell death ligand 1 (PD-L1) is a key mechanism of immune escape, and antibody blockade of the interaction has emerged as an effective immunotherapeutic strategy in some cancers. The role and relevance of the PD-1 checkpoint in Ewing sarcoma (EwS) is not yet understood. PROCEDURE: Here, we investigated expression of PD-L1 and PD-1 in EwS by immunohistochemistry analysis of pretherapeutic tumor biopsies and in tumor xenografts following treatment with human T cells engineered to express a chimeric antigen receptor (CAR) against the tumor-associated antigen G . PD-L1 surface expression in EwS cell lines was assessed by flow cytometry. RESULTS: PD-L1 expression was not detectable on tumor cells in any of the 60 EwS biopsies. Infiltrating PD-L1 positive T cells were found in one tumor, and four biopsies contained PD-1-positive T cells. Of 13 EwS cell lines, none constitutively expressed PD-L1 on the cell surface. Interferon-γ cytokine stimulation induced upregulation of the ligand on all cell lines. Adoptive therapy with CAR gene-modified T cells in a mouse model did not induce PD-L1 expression in EwS xenografts despite tumor infiltration with PD-1+ CD3+ T cells. CONCLUSIONS: EwS cells can upregulate PD-L1 under inflammatory conditions, but do not express the ligand in the pretherapeutic tumor microenvironment or postexposure to CAR T cells. PD-1 checkpoint blockade alone is thus unlikely to evoke potent immune responses against EwS. Identification of the relevant immune evasion strategies in EwS will be vital for the development of effective immune targeting strategies.
[Mh] Termos MeSH primário: Antígeno B7-H1/biossíntese
Regulação Neoplásica da Expressão Gênica
Proteínas de Neoplasias/biossíntese
Sarcoma de Ewing
Regulação para Cima
[Mh] Termos MeSH secundário: Adolescente
Adulto
Biópsia
Linhagem Celular Tumoral
Criança
Pré-Escolar
Feminino
Seres Humanos
Masculino
Sarcoma de Ewing/metabolismo
Sarcoma de Ewing/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (B7-H1 Antigen); 0 (CD274 protein, human); 0 (Neoplasm Proteins)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170905
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26719


  9 / 6155 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28938120
[Au] Autor:Shorter J
[Ad] Endereço:Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: jshorter@mail.med.upenn.edu.
[Ti] Título:Prion-like Domains Program Ewing's Sarcoma.
[So] Source:Cell;171(1):30-31, 2017 09 21.
[Is] ISSN:1097-4172
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Prion-like domains have emerged as important drivers of neurodegenerative disease. Now, Boulay et al. establish that the translocated prion-like domain of the oncogenic EWS-FLI1 fusion protein enables phase-separation events, which inappropriately recruit chromatin-remodeling factors to elicit the aberrant transcriptional programs underlying Ewing's sarcoma.
[Mh] Termos MeSH primário: Proteína EWS de Ligação a RNA
Sarcoma de Ewing
[Mh] Termos MeSH secundário: Seres Humanos
Proteínas de Fusão Oncogênicas
Príons
Proteína Proto-Oncogênica c-fli-1
Fatores de Transcrição
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (EWS-FLI fusion protein); 0 (Oncogene Proteins, Fusion); 0 (Prions); 0 (Proto-Oncogene Protein c-fli-1); 0 (RNA-Binding Protein EWS); 0 (Transcription Factors)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170923
[St] Status:MEDLINE


  10 / 6155 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28853588
[Au] Autor:Yang P; Evans S; Bali N; Ramasamy A; Evans R; Stevenson J; Jeys L; Grimer R
[Ad] Endereço:Royal Orthopaedic Hospital NHS Foundation Trust , UK.
[Ti] Título:Malignant bone tumours of the foot.
[So] Source:Ann R Coll Surg Engl;99(7):568-572, 2017 Sep.
[Is] ISSN:1478-7083
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Introduction Malignant osseous foot tumours are uncommon. Their oncological outcomes have been poorly documented in the literature so far. The aim of this study was to establish the incidence and to evaluate the oncological outcomes of such patients. Methods Our large orthopaedic oncology database was used to review 70 malignant osseous foot tumour patients. Results The age at diagnosis of malignant osseous foot tumours demonstrated a bimodal distribution peaking in the second and eighth decades of life. Overall, 55 primary malignant bone tumours of the foot (79%) were identified. The median duration from onset of symptoms to diagnosis was 52 weeks (interquartile range [IQR]: 17-104). Eight primary tumours (15%) underwent an accidental excision (ie intralesional excision of a malignant bone tumour where some of the tumour has been left behind, also known as a 'whoops procedure') prior to referral to our unit. Forty-six patients (84%) underwent surgery overall and thirteen of these developed recurrence or metastases. Seven of eight patients with a previous accidental excision underwent amputation. Fifteen osseous metastatic foot lesions were identified. The median length of foot symptoms to diagnosis was 24 weeks (IQR: 20-36 weeks). The median time to death following diagnosis of osseous foot metastases was 20.1 months (IQR: 11.3-27.8 months). Conclusions A high index of suspicion and awareness of clinical features of malignant osseous foot tumours are both essential to avoid diagnostic delays. Amputation is associated with a respectable outcome for patients who have undergone previous accidental excisions.
[Mh] Termos MeSH primário: Neoplasias Ósseas/diagnóstico
Ossos do Pé
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias Ósseas/mortalidade
Neoplasias Ósseas/cirurgia
Criança
Pré-Escolar
Condrossarcoma/diagnóstico
Condrossarcoma/mortalidade
Condrossarcoma/cirurgia
Feminino
Ossos do Pé/cirurgia
Seres Humanos
Lactente
Masculino
Meia-Idade
Osteossarcoma/diagnóstico
Osteossarcoma/mortalidade
Osteossarcoma/cirurgia
Estudos Retrospectivos
Sarcoma de Ewing/diagnóstico
Sarcoma de Ewing/mortalidade
Sarcoma de Ewing/cirurgia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170831
[St] Status:MEDLINE
[do] DOI:10.1308/rcsann.2017.0114



página 1 de 616 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde